| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2005 , Vol 47 , Num 2
EFFECT OF ARQ GAUZABAN A UNANIPATHY PRODUCT ON THE ISOLATED FROG HEART
Department of Pharmacology and Department of Pharmacognosy, N.E.T Pharmacy College, Mantralayam Road, Raichur, India
Viewed :
21844
-
Downloaded :
8320
Arq gauzaban (a clear aqueous distillate of the plant Onosma bracteatum) a unanipathy product recommended by the unanipathy practioners to strengthen the sick heart both pre and post operatively was studied. Despite its extensive use in unanipathy health care system, no systematic study has been reported so far. Hence, in the present study an effort was made to screen the product for its cardiac effects on isolated frog heart. Arq guazaban exhibited a positive inotropic effect on the isolated perfused frog heart. The main mechanism behind this pharmacological response appears to be through the calcium channels. The study thus further supports the use of arq guazaban as a myocardial strengthening agent in unanipathy health care practice.
Keywords :
ARQ GAUZABAN, POSITIVE INOTROPIC EFFECT, BETA BLOCKER, CALCIUM CHANNEL BLOCKER, ISOLATED FROG HEART
